NEW YORK (GenomeWeb) – Quanterix this week named PBL Assay Science a preferred partner for assay research and development.
Leveraging Quanterix's Simoa — a single-molecule array immunoassay technology for detecting and quantifying antigens and proteins — PBL will be able to enter new markets and strengthen its current product offerings, Quanterix said.
"We have built a robust line of ELISA, protein, and antibody products, and have extensive experience in developing and executing high-sensitivity biomarker assays," PBL CSO Thomas Lavoie said in a statement. "These capabilities are well complemented by Quanterix's single-molecule array technology to provide answers to problems in disease biology where basal levels of biomarker analytes have been extremely difficult to quantify."